News
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...
Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...
WITH the price of Mounjaro set to rise and concerns about long-term affordability and access, many may be looking to turn to alternative treatments, like Wegovy. But how do the two weight loss ...
New diabetes and obesity drugs, like Mounjaro and Ozempic, are changing people's relationships with food. While these drugs ...
inews.co.uk on MSN18h
'I'm bulk buying Mounjaro ahead of price hike — it's changed my life'
As the cost of Mounjaro jabs is set to increase by as much as 170 per cent, Jade Kay, who has already spent £2.4k on the drug ...
18h
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...
Indy100 on MSN22h
Is Trump to blame for the UK’s 170% Mounjaro price surge?
The cost of Mounjaro, a popular weight-loss injection, is set to rise sharply in the UK – from £122 to £330 – a 170 per cent increase starting this September. The price hike, confirmed by US ...
The Observer on MSN2h
Low prices and tariff threats test Big Pharma’s ties to UK
AstraZeneca chief is irked by cost of doing business as Eli Lilly raises price of Mounjaro after presidential pressure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback